Epigenetic suppression of the T-box subfamily 2 (TBX2) in human non-small cell lung cancer
Loading...
Files
Date
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI AG
Abstract
(1) The TBX2 subfamily of transcription factors (TBXs 2, 3, 4 and 5) are markedly down-regulated in human non-small cell lung cancer (NSCLC) and exert tumor suppressor effects in lung malignancy. Yet, mechanisms underlying suppressed expression of the TBX2 subfamily in NSCLC are elusive. Here, we interrogated probable epigenetic mechanisms in suppressed expression of the TBX2 subfamily in human NSCLC. (2) TBX2 subfamily gene expression and methylation levels in NSCLC and normal lung tissues were surveyed using publicly available RNA-sequence and genome-wide methylation datasets. Methylation β-values of the four genes were statistically compared between NSCLCs and normal lung tissues, correlated with gene expression levels, and interrogated with clinicopathological variables. Expression and methylation levels of TBXs were quantified in NSCLC cells using real-time PCR and methylation-specific PCR assays, respectively. Effects of the DNA methyltransferase inhibitor 5-azacytidine (Aza) on TBX2 subfamily expression were assessed in NSCLC cells. Impact of TBX2 subfamily expression on Aza-treated cells was evaluated by RNA interference. (3) All four TBXs were significantly hypermethylated in NSCLCs relative to normal lung tissues (p < 0.05). Methylation β-values of the genes, with exception of TBX2, were significantly inversely correlated with corresponding mRNA expression levels (p < 0.05). We found no statistically significant differences in hypermethylation levels of the TBX2 subfamily by clinicopathological features including stage and tobacco history. Expression levels of the TBX genes were overall suppressed in NSCLC cells relative to normal alveolar cells. Members of the subfamily were significantly hypermethylated in all tested NSCLC cell lines relative to normal alveolar cells. Treatment with Aza induced the expression of the TBX2 subfamily concomitant with NSCLC cell growth inhibition. Further, simultaneous knockdown of the four TBX genes markedly reduced anti-growth effects of Aza in NSCLC cells. (4) Our study sheds light on new epigenetic profiles in the molecular pathogenesis of human NSCLC. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
Description
Keywords
Epigenetic suppression, Methylation, Non-small cell lung cancer, Tbx2, Azacitidine, Carcinoma, non-small-cell lung, Cell line, tumor, Dna methylation, Down-regulation, Epigenesis, genetic, Female, Gene expression regulation, neoplastic, Humans, Lung neoplasms, Male, Multigene family, Neoplasm staging, T-box domain proteins, Transcription factor, Transcription factor tbx2, Unclassified drug, T box transcription factor, Antiproliferative activity, Article, Cell growth, Cell proliferation, Cell viability, Cell viability assay, Computer model, Controlled study, Down regulation, Epigenetics, Gene, Gene expression, Gene knockdown, Gene repression, Gene sequence, Genetic transfection, Growth inhibition, Histopathology, Human, Human cell, Human tissue, Ic50, Lung biopsy, Molecular pathology, Mrna expression level, Mtt assay, Non small cell lung cancer, Polymerase chain reaction, Protein expression, Real time polymerase chain reaction, Reverse transcription polymerase chain reaction, Rna interference, Upregulation, Cancer staging, Drug effect, Gene expression regulation, Genetic epigenesis, Genetics, Lung tumor, Pathology, Tumor cell line